Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 18.41M shares rose 3.4% year over year, ahead of the +2.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at +1.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.4% holds above the trailing-twelve-month pace of +2.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
18.41M+2.4% QoQ
Last fiscal yearDec 2025
17.99M+2.3% YoY
LTMMar 2026
18.08M+2.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%——
1 year+2.3%——
3-year CAGR+1.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
17.99M USD
Year-over-year change
+2.3%
4-year CAGR
+1.3%

Weighted Avg Shares vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 weighted avg shares of 18.08M shares is the 9th highest of the 10 companies compared; the peer median is 80.25M shares.
  • Its year-over-year change of +2.4% is the 6th highest of 9, against a peer median of +17.4%.
  • Over three fiscal years its annual growth of +1.4% compares with a peer median of +9.7%.
RIGL Competitors Peer median
Weighted Avg Shares for RIGL and competitors
Company Period LTM YoY 3-year CAGR
EXELExelixis, Inc.LTM Jul 2026262.28M -6.5%-5.5%
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
VSTMVerastem, Inc.LTM Mar 202680.25M +101.5%+62.5%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+9.3%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
ANLAdlai Nortye Ltd.LTM Jun 20247.76M —+7.9%
Peer median (excluding RIGL) 80.25M+17.4%+9.7%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue149.24M120.24M116.88M179.28M294.28M
Cost of Revenue1.08M1.75M7.11M18.65M19.62M
Gross Profit148.15M118.49M109.77M160.63M274.66M
Gross Margin99.3%98.5%93.9%89.6%93.3%
Research & Development65.24M60.27M24.52M23.38M33.3M
Selling, General & Admin91.89M112.45M105.74M113.06M115.9M
Operating Expenses160.65M174.04M130.26M136.44M149.2M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
EBITDA(11.29M)(53.87M)(16.98M)28.51M131.56M
EBITDA Margin-7.6%-44.8%-14.5%15.9%44.7%
Operating Income(12.5M)(55.55M)(20.49M)24.19M125.47M
Operating Margin-8.4%-46.2%-17.5%13.5%42.6%
Interest Income47K684K2.27M2.09M3.68M
Interest Expense4.86M3.71M6.87M7.92M7.32M
Other Income / Expenses(4.81M)(3.02M)(4.6M)(5.83M)(3.64M)
Income Before Tax(17.31M)(58.57M)(25.09M)18.37M121.83M
Pre-Tax Margin-11.6%-48.7%-21.5%10.2%41.4%
Income Tax Expense605K00881K(245.2M)
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (Basic)(1.10)(3.40)(1.44)0.9920.40
EPS (Diluted)(1.10)(3.40)(1.44)0.9919.48
Weighted Avg Shares17.05M17.24M17.4M17.58M17.99M
Weighted Avg Shares (Diluted)17.05M17.24M17.4M17.69M18.84M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.